Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Ellard, G A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ellard, G A
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

British Medical Bulletin 44:775-790 (1988)
© 1988 The British Council

research-article

Chemotherapy of leprosy

G A Ellard

Laboratory for Leprosy and Mycobacterial Research, National Institute for Medical Research London

Abstract

The rapid spread of dapsone-resistant strains of M. leprae during the 1970s, that resulted from the previous use of dapsone monotherapy for the treatment of leprosy, necessitated a radical new approach to the treatment of the disease. In response to this challenge, a Study Group convened by the World Health Organization in 1981 recommended that multibacillary patients should be treated to smear-negativity with a combination of once-monthly supervised doses of rifampicin together with daily self-administered dapsone and clofazimine. It was suggested that paucibacillary patients need only be treated for 6 months with monthly rifampicin plus daily dapsone. Some 2 million patients have already been treated with these recommended regiments which have been excellently tolerated and are proving to be highly effective.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.